The FCC is considering a petition filed by two municipal-run broadband networks that asked the FCC to preempt state laws that limit the expansion of government-owed networks. Today, ACI filed its comments pointing out how many of these networks are mismanaged, unprofitable and costly for consumers and taxpayers, as well as posing anticompetitive risks. ACI’s comments are filed with the […]
This piece, published in the Hill’s Congressional Blog by ACI’s president, Steve Pociask, discusses how the FCC’s restrictive wireless auction rules — rules that favor some bidders over others — is a recipe for failure. The article shows that the auction rules will limit the proceeds, which in encourage fewer TV broadcasters to give up their spectrum. That, […]
Over the last few years, there has been an increase in a type of ticket to live entertainment and sports events that does not have the consumer’s best interests at heart. This summer, “A-list” artists, including Arcade Fire, Eric Church, Garth Brooks and The Black Keys, will use this paperless system. From a convenience standpoint, […]
Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but the FDA needs to write the rules necessary to permit competitive entry. His piece is available to read and print at Forbes.
Have you ever tried to buy concert tickets and found out that all of the tickets were sold out in just a few minutes? Blame the scalpers? Blame the resellers? No, it is an inside job. This article, written by ACI president Steve Pociask, talks about how performing artists, concert venues and Ticketmaster are involved in holding back […]
This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs. These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics. Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients. The article calls on the FDA to accelerate its rulemaking and write […]
Lower Prices and Greater Access to Life-Saving Drugs Generic drugs have saved over a trillion dollars in healthcare costs between 2002 and 2011 by competing against name brand drugs. Another opportunity now exists to further reduce pharmaceutical drug expenditures involving a growing, but expensive, innovative class of drugs, called biologics. The introduction of their generic-like […]
The Food and Drug Administration (FDA) began approving generic (unbranded) prescription drugs around 30 years ago, and generic drugs are now saving consumers more than one trillion dollars per decade in healthcare costs over their brand named counterparts. Competition from generics has provided more options to doctors and better access to patients – at prices […]